{"title":"对 \"免疫检查点抑制剂治疗癌症患者的乙型肝炎功能性治愈：一种前景广阔的策略？\"和 \"肝细胞癌患者是免疫检查点抑制剂治疗乙型肝炎的理想研究人群 \"的回复","authors":"Hsien-Chen Mon, Yi-Hsiang Huang","doi":"10.1016/j.jhep.2024.10.045","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Financial disclosure funding</h2>No financial support was received for this letter.</section></section><section><section><h2>Funding funding</h2>None</section></section><section><section><h2>Conflict-of-interest statement COI</h2>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</section></section><section><section><h2>Author contributions author-disclosure</h2>HCM: manuscript drafting; YHH: critical expert review and revision of the manuscript.</section></section><section><section><h2>Acknowledgements</h2>There are no additional acknowledgements.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"29 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reply to “Immune checkpoint inhibitor therapy for functional cure of hepatitis B in cancer patients: a promising strategy?” and “Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B”\",\"authors\":\"Hsien-Chen Mon, Yi-Hsiang Huang\",\"doi\":\"10.1016/j.jhep.2024.10.045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h2>Section snippets</h2><section><section><h2>Financial disclosure funding</h2>No financial support was received for this letter.</section></section><section><section><h2>Funding funding</h2>None</section></section><section><section><h2>Conflict-of-interest statement COI</h2>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</section></section><section><section><h2>Author contributions author-disclosure</h2>HCM: manuscript drafting; YHH: critical expert review and revision of the manuscript.</section></section><section><section><h2>Acknowledgements</h2>There are no additional acknowledgements.</section></section>\",\"PeriodicalId\":15888,\"journal\":{\"name\":\"Journal of Hepatology\",\"volume\":\"29 1\",\"pages\":\"\"},\"PeriodicalIF\":26.8000,\"publicationDate\":\"2024-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jhep.2024.10.045\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2024.10.045","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Reply to “Immune checkpoint inhibitor therapy for functional cure of hepatitis B in cancer patients: a promising strategy?” and “Hepatocellular Carcinoma Patients as an Ideal Study Population for Immune Checkpoint Inhibitors in Hepatitis B”
Section snippets
Financial disclosure funding
No financial support was received for this letter.
Funding funding
None
Conflict-of-interest statement COI
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Author contributions author-disclosure
HCM: manuscript drafting; YHH: critical expert review and revision of the manuscript.
期刊介绍：
The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
